心肌细胞中的STING激活通过NF-κB介导的炎症反应驱动高度相关心力衰竭
Lintao Wang1, Suya Zhang1, Hongxia Liu1
1Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 210009, China.
Biochimica et biophysica acta. Molecular basis of disease
|December 24, 2023
概括
干扰素基因刺激器 (STING) 通过激活NF-κB通路来驱动心脏缩和心力衰竭. 抑制STING可能为心脏病提供新的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 免疫学 免疫学 免疫学
- 具有天生的免疫力.
背景情况:
- 天生的免疫力在心脏缩和失败中起着至关重要的作用.
- 在这些条件下,心肌细胞衍生的干扰素基因刺激器 (STING) 的作用和机制在很大程度上仍未被探索.
研究的目的:
- 调查心肌细胞衍生的STING是否有助于心脏缩和心脏衰竭.
- 为了阐明涉及的潜在分子机制.
主要方法:
- 分析人类心脏缩组织和小鼠模型 (血管新生素II和TAC).
- 在体外研究中使用心肌细胞培养与STING激活/Knockout.
- 在小鼠模型中药理上抑制和遗传删除STING.
主要成果:
- 在人类心脏缩和心脏压力的小鼠模型中,STING表达和激活增加了.
- 在实验室中,STING激活诱导了心肌细胞缩,这取决于STING.
- 在小鼠中,STING删除或抑制减弱了心脏缩和功能障碍.
- 特定于心肌细胞的STING激活导致心脏缩和失败.
- 通过STING-NF-κB信号轴,而不是TBK1或自,调解了STING诱导的心脏缩和衰竭.
结论:
- STING-NF-κB轴是导致心脏缩和衰竭的炎症反应的关键调解器.
- STING代表了治疗心脏缩相关心力衰竭的有前途的治疗标.
相关概念视频
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Inflammation
53.4K
Overview
53.4K
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K


